Börskollen - Aktier, fonder och ekonominyheter
Börskollen
•Placeringstips: Bortom utdelningssäsongen: Säkra månatlig ränteavkastning – 11-15 % årsränta (annons)

Pressmeddelanden från Nykode Therapeutics

 Bevaka pressreleaser
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts
06 nov 2024 17:00
Nykode Therapeutics
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe14 aug 2024 07:00
Nykode Therapeutics
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines20 jun 2024 07:00
Nykode Therapeutics
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting11 jun 2024 07:00
Nykode Therapeutics
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy14 maj 2024 07:15
Nykode Therapeutics
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer14 maj 2024 07:00
Nykode Therapeutics
Nykode Therapeutics - Quarterly report Q1 202419 apr 2024 07:00
Nykode Therapeutics
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer21 mar 2024 07:00
Nykode Therapeutics
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer19 mar 2024 07:00
Nykode Therapeutics
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases15 nov 2023 10:30
Nykode Therapeutics
Nykode Therapeutics - Quarterly report Q3 202309 okt 2023 06:45
Nykode Therapeutics
Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston20 sep 2023 16:06
Nykode Therapeutics
Nykode Therapeutics Announces Advances in Clinical Pipeline and Research05 sep 2023 07:00
Nykode Therapeutics
Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer23 aug 2023 06:45
Nykode Therapeutics
Nykode Therapeutics - Quarterly report Q2 202301 jun 2023 06:45
Nykode Therapeutics
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer30 maj 2023 18:00
Nykode Therapeutics
Nykode Therapeutics to Present at Jefferies Healthcare Conference18 apr 2023 17:00
Nykode Therapeutics
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer22 feb 2023 13:00
Nykode Therapeutics
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 202310 feb 2023 06:45
Nykode Therapeutics
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer07 feb 2023 13:00
Nykode Therapeutics
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference23 dec 2022 11:00
Nykode Therapeutics
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference20 dec 2022 06:45
Nykode Therapeutics
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers19 dec 2022 06:45
Nykode Therapeutics
Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership06 dec 2022 16:45
Nykode Therapeutics
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer16 nov 2022 16:00
Nykode Therapeutics
Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 202207 nov 2022 08:00
Nykode Therapeutics
Nykode Therapeutics to present at two upcoming investor conferences in November 26 okt 2022 16:30
Nykode Therapeutics
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit27 sep 2022 06:45
Nykode Therapeutics
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate09 sep 2022 17:00
Nykode Therapeutics
Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference22 aug 2022 06:45
Nykode Therapeutics
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 202216 jun 2022 09:00
Nykode Therapeutics
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange01 jun 2022 08:00
Nykode Therapeutics
Nykode Therapeutics to Present at Jefferies Healthcare Conference09 maj 2022 06:45
Nykode Therapeutics
Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer08 apr 2022 19:00
Nykode Therapeutics
Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting08 mar 2022 22:30
Nykode Therapeutics
Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting14 feb 2022 06:45
Nykode Therapeutics
Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference11 feb 2022 06:45
Nykode Therapeutics
Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer28 dec 2021 06:45
Nykode Therapeutics
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate